This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features impact the development of resistance, and to test a novel combination approach of DNA repair inhibition and targeted therapy to prevent resistance from emerging. The research will leverage clinical samples, cell lines, and patient-derived xenograft models to characterize the role of chromosomal instability and extra-chromosomal DNA amplifications in driving rapid resistance. The goal is to transform targeted therapy for colorectal cancer and improve patient outcomes. The project period runs from March 1, 2025 to February 28, 2027.
Generated 3/18/25, 3:46 AM